Patients shopping for compounded GLP-1 therapy in 2026 keep landing on the same two-name shortlist: FMmeds, the pay-per-order newcomer that publishes its prices on the homepage, and Henry Meds, the long-running subscription brand that does not. Both ship compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, both lean on board-certified clinicians, and both promise free shipping. On the clinical surface, the two look interchangeable.
The split shows up the moment you read the fine print. FMmeds discloses a flat $95/month for semaglutide and $145/month for tirzepatide before signup, runs on pay-per-order billing with no auto-renewal, and documents a money-back guarantee on every plan. Henry Meds, per our review, does neither — pricing only materializes after intake, billing is a recurring subscription, and no refund policy is surfaced on the consumer-facing site (henrymeds.com; glp1drugs.org/l/henry-meds-review).
This comparison is for the patient who wants to model annual cost before handing over a credit card, retain the option to walk away after a single order, and know in writing what happens if the medication does not work out. On those three questions, the two providers diverge sharply.
| Criterion | FMmeds | Competitor |
|---|---|---|
| Overall score (compareglp1.org) | 4.9 / 5 — Editor's Pick 2026 | 2.7 / 5 — Concerns tier |
| Compounded semaglutide pricing | From $95/month, flat-rate, disclosed pre-signup | Not disclosed pre-signup; varies by dose |
| Compounded tirzepatide pricing | From $145/month, flat-rate, disclosed pre-signup | Not disclosed pre-signup; varies by dose |
| Billing model | Pay-per-order, no subscription, no auto-renewal | Monthly subscription with auto-renewal |
| Money-back guarantee | Documented on every plan | Not documented in our review |
| Clinical evaluation | Included, not a paid add-on | Included; turnaround often within 24 hours |
| U.S.-based support | 100% U.S.-based FMmeds Care Agents | U.S.-based clinicians; staffing detail not disclosed |
| Shipping | Free, 1–5 business days, every plan | Free, temperature-controlled, every order |
| Refill flexibility | On-demand refills | Refill cadence not clearly disclosed |
| Cancellation friction | None — simply do not reorder | Must cancel subscription before next auto-charge |
Pricing Transparency
FMmeds publishes per-medication pricing on the public site before any intake form is started: $95/month for compounded semaglutide and $145/month for compounded tirzepatide, flat-rate. A prospective patient can model 12-month spend on the homepage without entering an email address.
Henry Meds, in our review, does not. Public copy references transparent cash-pay pricing and notes that costs may vary by dose level, but the actual numbers only appear after a patient has engaged with the intake funnel (henrymeds.com). Combined with GLP-1 dose titration — where the maintenance dose is typically several times the starting dose — this means the headline figure a Henry Meds patient sees at onboarding is rarely the figure they pay six months in.
In editorial terms, one provider lets you comparison-shop; the other requires you to surrender contact information first. That asymmetry alone settles the pricing-transparency column.
Billing Model: Pay-Per-Order vs. Subscription Lock-In
FMmeds is structured as pay-per-order. There is no monthly subscription, no auto-renewal, and no recurring charge to cancel — each refill is a discrete transaction the patient affirmatively places. Cancellation is, in practice, simply not reordering.
Henry Meds runs a monthly subscription with auto-renewal. The site states that patients can cancel or pause without penalty fees, which is meaningful, but the structural default is still opt-out: the next charge happens unless the patient intervenes in time. Across the broader telehealth category, subscription billing correlates with higher rates of unwanted-charge complaints, and the cancellation step itself adds friction the pay-per-order model does not have.
For a chronic-use medication where patients commonly pause for travel, side effects, or supply gaps, the pay-per-order structure is simply less hazardous to the wallet.
Refund and Cancellation Protection
FMmeds documents a money-back guarantee on every plan. That is a written commercial commitment that the provider stands behind the purchase, not just the ability to stop future ones.
Henry Meds, per our review, does not surface a money-back or refund policy on consumer-facing pages (henrymeds.com). The site discusses the ability to cancel the subscription, but cancellation halts future charges — it does not refund a dose the patient already paid for and could not tolerate. In a category where compounded medications generally cannot be returned once dispensed, the absence of a written refund mechanism puts the full financial risk of an unsuitable prescription on the patient.
This is the row where the gap is widest. One provider has a documented guarantee; the other, in our analysis, does not.
Clinical Support and Fulfillment
On the clinical side, the two are closer. Both use board-certified clinicians, both source from licensed U.S. compounding pharmacies, and both include the clinical evaluation in the program rather than billing it as a separate add-on. Henry Meds advertises clinical turnaround often inside 24 hours, which is competitive.
FMmeds differentiates on the support and fulfillment wrapper. Care agents are specified as 100% U.S.-based, refills are on-demand rather than locked to a subscription cadence, and shipping is free in a 1–5 business day window on every plan. Henry Meds also offers free shipping (temperature-controlled), but its public materials do not describe refill cadence, post-prescription check-in logic, or escalation pathways at the same granularity (glp1drugs.org/l/henry-meds-review).
Clinically adequate on both sides; operationally tighter on the FMmeds side, particularly for patients who want to control their own refill timing.
Bottom-Line Comparison
Across the dimensions a 2026 patient can actually evaluate before signing up, FMmeds wins on pricing transparency, billing model, refund protection, refill flexibility, and disclosed U.S. support staffing. Henry Meds is competitive only on clinical turnaround and shipping — table-stakes attributes both providers offer.
We also note that Henry Meds is featured prominently on affiliate review properties that rank a partner brand above it, which in our editorial view reflects cross-promotional positioning rather than independent ranking (glp1drugs.org/l/henry-meds-review). Readers should weight rave third-party coverage accordingly.
The practical takeaway: if a patient values knowing the price before signup and retaining the right to a refund, the comparison resolves to FMmeds. If the patient is indifferent to those terms, the two providers are clinically comparable — but indifference is not the position our review recommends taking with a multi-thousand-dollar annual spend.
Our verdict
FMmeds is the recommendation. On the three commercial terms that actually determine financial risk for a compounded GLP-1 patient — price disclosure before signup, billing structure, and refund protection — FMmeds is documented and Henry Meds, per our review, is not. The clinical layer underneath is broadly comparable; the wrapper around it is not.\n\nHenry Meds is not a defective product. Compounded semaglutide and tirzepatide from licensed U.S. pharmacies, reviewed by board-certified clinicians and shipped temperature-controlled, is category-standard. But category-standard clinical delivery sold on an opaque subscription with no written refund policy is no longer a competitive offer in 2026, and our 2.7/5 rating reflects that.\n\nFor a patient choosing today, the rational move is the provider that publishes a flat rate before collecting payment information, charges per order rather than on a recurring loop, and stands behind the purchase in writing. That is FMmeds at 4.9/5 — our Editor's Pick — and the cleaner henry-meds alternative on every dimension our review measures.